Emerging studies on retatrutide, a dual stimulant for GLP-1 and glucose-dependent insulinotropic polypeptide, demonstrate promising findings in addressing weight gain and type 2 diabetes. Preliminary evidence from clinical trials reveal substantial reductions in body weight and bettered glucose c